MSACL 2019 US Abstract

Clinical Evaluation of Interaction of Phytoestrogenic Botanical Dietary Supplements with Drug Metabolism in Women

Luying Chen (1,2), Jaewoo Choi (1), Scott Leonard (1), Alyssa Tonsing-Carter (2), Suzanne Banuvar (2), Elena Barengolts (2), Marlos Viana (2), Richard B. van Breemen (1,2*)
(1) Linus Pauling Institute, College of Pharmacy, Oregon State University, Corvallis, OR 97331 (2) UIC/NIH Center for Botanical Dietary Supplements Research, Chicago, IL 60612

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Luying Chen (Presenter) Linus Pauling Institute, Oregon State University

Presenter Bio: Luying Chen is a fifth-year doctoral student in Oregon State University College of Pharmacy. Her dissertation research focuses on in vivo and in vitro investigation of the safety of botanical dietary supplements, including two Phase I clinical trials for evaluating interactions of hop and red clover dietary supplements with drug metabolism in women by using UHPLC-MS/MS, and in vitro assays for kinetics of components displaying cytochrome P450 inhibitive activity identified from licorice. She is an expert in LC-MS/MS quantitative analysis of small molecules and proteins at peptide level in biological and clinical specimens. She developed excellent experimental skills and critical scientific thinking throughout her two industrial internship experiences at Shire and Takeda Pharmaceuticals.

Relevant Financial Disclosures (within past 24 months) No relevant financial relationship(s) to disclose. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

Hops (Humulus lupulus L.) and red clover (Trifolium pratense L.) containing phytoestrogens are being used by women for the management of menopausal symptoms. Our in vitro data predicted that these botanical dietary supplements can inhibit certain cytochrome P450 enzymes. Two Phase I clinical trials of 16 women each were carried out to test for possible drug-botanical interactions. The pharmacokinetics of probe substrate drugs targeting CYP1A2, CYP3A4/5, CYP2C9, and CYP2D6 were compared before and after consumption of each supplement for 14 days. UHPLC-MS/MS was used for quantitative analysis of the drugs in serum. Pharmacokinetics modeling indicated no clinically relevant botanical interactions.